These obstacles were recently addressed by the development of a novel rapid BRCA1/2 POC assay aimed at improving the clinical management of patients with BC and associated co-morbidities (https://gtr.ukri.org/projects?ref=103993). This evidence concerns the gene BRCA1 and breast cancer.